🧬Insilico Medicine Designs First-In-Class PROTAC Targeting PKMYT1 Cancer Pathway
Insilico Medicine Designs First-In-Class PROTAC Targeting P…
TL;DR
Insilico Medicine used its Chemistry42 platform to design a first-in-class PROTAC with a dual-action mechanism targeting PKMYT1, a notoriously challenging canc…
Insilico Medicine used its Chemistry42 platform to design a first-in-class PROTAC with a dual-action mechanism targeting PKMYT1, a notoriously challenging cancer target. The announcement adds to a year of record AI-originated IND filings from companies including Recursion, BenevolentAI, Absci, and Generate Biomedicines.
Key Points
First-in-class dual-action PROTAC
Targets PKMYT1, an undruggable cancer target
Designed via Chemistry42 generative platform
Why It Matters
PROTACs against undruggable targets are the highest-leverage proof point AI drug discovery can deliver, and Insilico keeps producing them at a cadence pharma cannot match.
Frequently Asked Questions
Why does this matter?
PROTACs against undruggable targets are the highest-leverage proof point AI drug discovery can deliver, and Insilico keeps producing them at a cadence pharma cannot match.
What happened?
Insilico Medicine used its Chemistry42 platform to design a first-in-class PROTAC with a dual-action mechanism targeting PKMYT1, a notoriously challenging canc…
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.